| Praveen Kumar Vikraman, MD | |
|
200 Medical Center Dr Ste 2o, Hazard, KY 41701-9422 | |
| (606) 439-8450 | |
| Not Available |
| Full Name | Praveen Kumar Vikraman |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Infectious Disease |
| Location | 200 Medical Center Dr Ste 2o, Hazard, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952888166 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 311237 (New York) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | 57666 (Kentucky) | Primary |
| Entity Name | Appalachian Regional Healthcare Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528148012 PECOS PAC ID: 0840107835 Enrollment ID: O20031125000520 |
News Archive
Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
A three-judge panel in Atlanta will hear oral arguments in the lawsuit brought by 26 states. At issue is whether a Florida judge's ruling to strike down large portions of the sweeping overhaul should be reversed.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.
› Verified 6 days ago
| Entity Name | Arh Tug Valley Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639949696 PECOS PAC ID: 4183953805 Enrollment ID: O20190905002344 |
News Archive
Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
A three-judge panel in Atlanta will hear oral arguments in the lawsuit brought by 26 states. At issue is whether a Florida judge's ruling to strike down large portions of the sweeping overhaul should be reversed.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Praveen Kumar Vikraman, MD 200 Medical Center Dr Ste 2o, Hazard, KY 41701-9422 Ph: (606) 439-8450 | Praveen Kumar Vikraman, MD 200 Medical Center Dr Ste 2o, Hazard, KY 41701-9422 Ph: (606) 439-8450 |
News Archive
Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
A three-judge panel in Atlanta will hear oral arguments in the lawsuit brought by 26 states. At issue is whether a Florida judge's ruling to strike down large portions of the sweeping overhaul should be reversed.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.
› Verified 6 days ago
Dr. Raymond Elsoueidi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
Dr. Gregory Balabanian, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7510 Fax: 606-439-6793 | |
Dr. Thomas E. Karelis Jr., MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 311 Roy Campbell Dr, Hazard, KY 41701 Phone: 606-487-0776 Fax: 606-487-0777 | |
Vidya B Yalamanchi, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7510 Fax: 606-439-6793 | |
Dr. Jeffery Prater, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 271 E Main St, Hazard, KY 41701 Phone: 606-439-1316 Fax: 606-439-3922 | |
Dr. Samuel Dean Bailey, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7902 | |
Mr. Ionut Stefanescu Sturz, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 311 Roy Campbell Drive, Hazard, KY 41701 Phone: 606-487-0776 Fax: 606-487-0777 |